MX2022009477A - Metodos para el tratamiento de sintomas neurologicos asociados con las enfermedades de almacenamiento lisosomico. - Google Patents
Metodos para el tratamiento de sintomas neurologicos asociados con las enfermedades de almacenamiento lisosomico.Info
- Publication number
- MX2022009477A MX2022009477A MX2022009477A MX2022009477A MX2022009477A MX 2022009477 A MX2022009477 A MX 2022009477A MX 2022009477 A MX2022009477 A MX 2022009477A MX 2022009477 A MX2022009477 A MX 2022009477A MX 2022009477 A MX2022009477 A MX 2022009477A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- lysosomal storage
- storage diseases
- neurological symptoms
- symptoms associated
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 208000015439 Lysosomal storage disease Diseases 0.000 title abstract 3
- 206010060860 Neurological symptom Diseases 0.000 title abstract 2
- 208000012902 Nervous system disease Diseases 0.000 abstract 3
- 210000005013 brain tissue Anatomy 0.000 abstract 3
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
- A61B6/03—Computed tomography [CT]
- A61B6/037—Emission tomography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- High Energy & Nuclear Physics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Radiology & Medical Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
Abstract
Se proporcionan métodos para tratar o prevenir los síntomas y trastornos neurológicos que están asociados con, por ejemplo, las enfermedades de almacenamiento lisosómico. Los métodos incluyen la mejora de la conectividad neuronal dentro del cerebro de un sujeto, el aumento del volumen de tejido cerebral, o la prevención o el retraso de la pérdida de volumen de tejido cerebral en un sujeto. También se proporcionan métodos para controlar la progresión o regresión de un trastorno neurológico, o para evaluar la aparición de un trastorno neurológico, asociado a una enfermedad de almacenamiento lisosómico, en los que se mide el volumen de tejido cerebral del sujeto.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062969568P | 2020-02-03 | 2020-02-03 | |
| US202063029154P | 2020-05-22 | 2020-05-22 | |
| US202063072714P | 2020-08-31 | 2020-08-31 | |
| PCT/IB2021/050879 WO2021156769A1 (en) | 2020-02-03 | 2021-02-03 | Methods for treating neurological symptoms associated with lysosomal storage diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022009477A true MX2022009477A (es) | 2022-08-22 |
Family
ID=74592326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022009477A MX2022009477A (es) | 2020-02-03 | 2021-02-03 | Metodos para el tratamiento de sintomas neurologicos asociados con las enfermedades de almacenamiento lisosomico. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210251982A1 (es) |
| EP (1) | EP4100009A1 (es) |
| JP (1) | JP2023512366A (es) |
| KR (1) | KR20220136887A (es) |
| CN (1) | CN115427038A (es) |
| AU (1) | AU2021215396A1 (es) |
| BR (1) | BR112022014553A2 (es) |
| CA (1) | CA3166777A1 (es) |
| IL (1) | IL295255A (es) |
| MX (1) | MX2022009477A (es) |
| TW (1) | TW202142236A (es) |
| WO (1) | WO2021156769A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11857512B2 (en) | 2020-07-24 | 2024-01-02 | Genzyme Corporation | Pharmaceutical compositions comprising venglustat |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE640616A (es) | 1962-12-19 | |||
| US3492397A (en) | 1967-04-07 | 1970-01-27 | Warner Lambert Pharmaceutical | Sustained release dosage in the pellet form and process thereof |
| US4060598A (en) | 1967-06-28 | 1977-11-29 | Boehringer Mannheim G.M.B.H. | Tablets coated with aqueous resin dispersions |
| US3538214A (en) | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
| US4173626A (en) | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
| GB0400812D0 (en) | 2004-01-14 | 2004-02-18 | Celltech R&D Ltd | Novel compounds |
| UA118248C2 (uk) * | 2011-03-18 | 2018-12-26 | Джензім Корпорейшн | Інгібітори глюкозилцерамідсинтази |
| JOP20130273B1 (ar) * | 2012-09-11 | 2021-08-17 | Genzyme Corp | مثبطات انزيم (سينثاز) غلوكوسيل سيراميد |
| JO3713B1 (ar) * | 2013-03-15 | 2021-01-31 | Genzyme Corp | أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت |
| WO2015089067A1 (en) | 2013-12-11 | 2015-06-18 | Genzyme Corporation | Glucosylceramide synthase inhibitors |
| TW201642855A (zh) * | 2015-03-10 | 2016-12-16 | 健臻公司 | 用於治療蛋白質病變之方法 |
| KR101865404B1 (ko) * | 2016-02-05 | 2018-06-07 | 경북대학교 산학협력단 | 혈관내피성장인자를 과발현한 줄기세포를 유효성분으로 포함하는 퇴행성 신경질환의 예방 또는 치료용 약학적 조성물 |
| BR112021015346A2 (pt) * | 2019-02-04 | 2021-10-05 | Prilenia Neurotherapeutics Ltd. | Uso de pridopidina de baixa dose para a doença de parkinson e outras doenças associadas ao parkinsonismo |
-
2021
- 2021-02-03 AU AU2021215396A patent/AU2021215396A1/en active Pending
- 2021-02-03 WO PCT/IB2021/050879 patent/WO2021156769A1/en unknown
- 2021-02-03 KR KR1020217038776A patent/KR20220136887A/ko unknown
- 2021-02-03 CN CN202180025025.5A patent/CN115427038A/zh active Pending
- 2021-02-03 MX MX2022009477A patent/MX2022009477A/es unknown
- 2021-02-03 TW TW110104027A patent/TW202142236A/zh unknown
- 2021-02-03 BR BR112022014553A patent/BR112022014553A2/pt unknown
- 2021-02-03 CA CA3166777A patent/CA3166777A1/en active Pending
- 2021-02-03 EP EP21704944.4A patent/EP4100009A1/en active Pending
- 2021-02-03 JP JP2021564953A patent/JP2023512366A/ja active Pending
- 2021-02-03 IL IL295255A patent/IL295255A/en unknown
- 2021-02-03 US US17/166,863 patent/US20210251982A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210251982A1 (en) | 2021-08-19 |
| EP4100009A1 (en) | 2022-12-14 |
| KR20220136887A (ko) | 2022-10-11 |
| JP2023512366A (ja) | 2023-03-27 |
| WO2021156769A1 (en) | 2021-08-12 |
| CN115427038A (zh) | 2022-12-02 |
| TW202142236A (zh) | 2021-11-16 |
| BR112022014553A2 (pt) | 2022-09-20 |
| CA3166777A1 (en) | 2021-08-12 |
| IL295255A (en) | 2022-10-01 |
| AU2021215396A1 (en) | 2022-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wen et al. | The perineuronal ‘safety’net? Perineuronal net abnormalities in neurological disorders | |
| Javaid et al. | Visual and ocular manifestations of Alzheimer’s disease and their use as biomarkers for diagnosis and progression | |
| Jeong | EEG dynamics in patients with Alzheimer's disease | |
| Dorey et al. | The clinical features of albinism and their correlation with visual evoked potentials | |
| Moreau et al. | Modulation of dysarthropneumophonia by low‐frequency STN DBS in advanced Parkinson's disease | |
| US8244341B2 (en) | Method and device for determining depressive disorders by measuring bioelectromagnetic signals of the brain | |
| Bliwise et al. | Phasic muscle activity in sleep and clinical features of Parkinson disease | |
| Sommer et al. | Nondipping in Parkinson's disease | |
| Matei et al. | Autonomic impairment in patients with migraine. | |
| MX2022009477A (es) | Metodos para el tratamiento de sintomas neurologicos asociados con las enfermedades de almacenamiento lisosomico. | |
| MX341316B (es) | Poblacion de celulas madre neurales para tratar y/o revertir enfermedades y/o trastornos neurodegenerativos. | |
| WO2017156279A3 (en) | Methods and systems for assessing infertility and ovulatory function disorders | |
| Kopal et al. | Changes of retina are not involved in the genesis of visual hallucinations in Parkinson’s disease | |
| Rankin et al. | Corneal sensitivity in healthy, immature, and adult alpacas | |
| Nikolić et al. | The presence of dysautonomia in different subgroups of myasthenia gravis patients | |
| IL285304A (en) | Methods for treating symptoms and disorders associated with lysosomal storage diseases | |
| Hirobumi | The effect of epipharyngeal abrasive therapy (EAT) on the baroreceptor reflex (BR) | |
| Abo-Elfetoh et al. | The relationship between auditory brainstem response, nerve conduction studies, and metabolic risk factors in type II diabetes mellitus | |
| RANGANATHAN | INTRAVENTRICULAR SCHWANNOMA-A RARE CASE REPORT | |
| Brooks et al. | Time parameters of the blink reflex in normal subjects | |
| Mathew | The Clinical Manifestation of Primary Progressive Aphasia | |
| Lesenskyj et al. | (393) Neuropathic pain reduction with scrambler therapy treatment | |
| Kopishinskaya et al. | E12 Retinal layers’ thickness as a potential biomarker of huntington’s disease | |
| Candia-Rivera et al. | The coupling between brain connectivity and heartbeat dynamics unveils the altered interoceptive mechanisms in Parkinson's disease | |
| Oknina et al. | O171 The role of cortex-brainstem integration in auditory perception |